We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pathologic ‘Fused Gland’ as a Prognostic Factor for Prostate Cancer.
- Authors
Noguchi, Sumio; Kubota, Yoshinobu; Kondoh, Iichirou; Harada, Masaoki; Masuda, Mitsunobu; Uemura, Hiroji; Hosaka, Masahiko
- Abstract
We examined the significance of a pathologic ‘fused gland’ according to the WHO-Mostofi classification for predicting prognosis in hormonally treated prostate cancer. Of 284 newly diagnosed patients receiving hormone therapy, 60 patients had specimens with no ‘medullary’ or ‘column-cord’ elements. Twenty-five of these had a ‘fused gland’, while 35 did not. Survival of these patients was analyzed. Cause-specific survival of the patients with no medullary or column-cord elements showed a significantly better prognosis compared to others. Furthermore, the patients whose specimens contained a ‘fused gland’ component had significantly poorer survival than those without that component, suggesting that the ‘fused gland’ component is a poor prognostic factor for survival in patients with hormonally treated prostate cancer.Copyright © 2000 S. Karger AG, Basel
- Subjects
PROSTATE cancer; ADENOCARCINOMA; CANCER treatment; ANDROGENS; PROGNOSIS; SYMPTOMS
- Publication
Urologia Internationalis, 2000, Vol 65, Issue 2, p84
- ISSN
0042-1138
- Publication type
Article
- DOI
10.1159/000064845